Endocrinology

California's Governor Signs Bill for State to Produce Its Own Biosimilars, Insulins

September 29, 2020

Skylar Jeremias

Article

California has become the first state to implement a policy to produce and distribute its own drug products to help lower costs.

Stakeholders Joust Over Biosimilar Availability at PCOC20

September 25, 2020

Tony Hagen

Article

A diverse panel from practice, payer, and wholesale perspectives convened at The American Journal of Managed Care®'s Patient-Centered Oncology Care® 2020 virtual conference to hash out one of the hottest issues in biosimilar availability right now.

Contributor: Drug Delivery Devices Help Originator Companies Retain Market Share

September 19, 2020

Isha Bangia, PharmD, MBA

Article

Amgen's Onpro autoinjector device for pegfilgrastim is a stunning example of how product differentiation via drug delivery devices can protect market share in the biologics market.

ACP Calls for Biologics Marketplace Reforms

September 16, 2020

Tony Hagen

Article

The American College of Physicians (ACP) said many reforms are needed to install appropriate checks and balances in the biologic drugs marketplace.

Rep Grothman Introduces Bill for Automatic Insulin Biosimilar Interchangeablity

September 15, 2020

Skylar Jeremias

Article

Representative Glenn Grothman, R-Wisconsin, says interchangeability for insulins makes sense based on the savings potential and safety record of these agents.

Report: PBM "Reforms" Leave Biosimilars Out in the Cold

September 2, 2020

Tony Hagen

Article

It’s same old, same old when it comes to pharmacy benefit manager (PBM) contracts despite much touted reforms, authors of a review contend.

Investigators Eye Gaps in Biosimilar Assessment Reports

August 31, 2020

Deana Ferreri, PhD

Article

Health technology tssessments play an important role in building confidence for use of biosimilars, yet very few meet criteria for thoroughness.

Biocon, Mylan Launch Semglee and Seek Biosimilar, Interchangeable Status

August 31, 2020

Tony Hagen

Article

For all intents and purposes, Semglee is a biosimilar insulin, but official biosimilar status is needed to clinch the marketing aspect.

Expert Opinion Roundup: New Insulin and Biosimilar Regulation

August 26, 2020

Skylar Jeremias

Article

Opinion leaders discuss the significance of regulatory changes affecting biosimilar and insulin products.

British Columbia Moves Into Third Phase of Mandatory Switching

August 25, 2020

Tony Hagen

Article

The statistics show that for the Rocky Mountain province, biosimilar savings are pouring into the health care system and allowing for significantly greater access.

x